{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Response was assessed by the International Workshop Criteria for Non-Hodgkin's Lymphoma. Complete Response is disappearance of all enhancing lesions on magnetic resonance imaging of the brain. Partial Response is a reduction of enhancing tumor volume by more than 50% for at least 4 weeks. Progressive Disease is an increase of tumor volume of more than 25% or occurrence of new lesions.","groups":[{"description":"Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.\n\nMethotrexate: 6000 mg/m\\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.\n\nRituximab: 375 mg/m\\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate\n\nLeucovorin: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes","id":"OG000","title":"Rituximab, High-Dose Methotrexate & Leucovorin Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two participants were not evaluable. One participant received one cycle of therapy and one was not evaluable due to treatment failure.","reportingStatus":"POSTED","timeFrame":"At the end of 6 cycles or 12 weeks of treatment","title":"Number of Participants With Response to Treatment After Rituximab, High-Dose Methotrexate (R-HD-MTX) Induction","type":"SECONDARY","unitOfMeasure":"Participants"}